2025
Neural Variability and Cognitive Control in Individuals With Opioid Use Disorder
Ye J, Mehta S, Peterson H, Ibrahim A, Saeed G, Linsky S, Kreinin I, Tsang S, Nwanaji-Enwerem U, Raso A, Arora J, Tokoglu F, Yip S, Hahn C, Lacadie C, Greene A, Constable R, Barry D, Redeker N, Yaggi H, Scheinost D. Neural Variability and Cognitive Control in Individuals With Opioid Use Disorder. JAMA Network Open 2025, 8: e2455165. PMID: 39821393, PMCID: PMC11742521, DOI: 10.1001/jamanetworkopen.2024.55165.Peer-Reviewed Original ResearchConceptsDecreased cognitive controlCognitive controlOpioid use disorderCueing paradigmResting-stateHC participantsUse disorderBrain statesBrain dynamicsHealthy controlsNeural mechanismsCognitive processesNeural variabilityFMRIBehavioral implicationsImpaired abilityBrainAccuracy scoresMagnetic resonance imagingDynamic alterationsParticipantsCase-control studyDisordersParadigmImpacts millions
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipants